Richard W Joseph

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Richard W Joseph
    Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida
    Cancer Immunol Res 3:18-22. 2015
  2. pmc Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma
    Richard W Joseph
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Immunother 35:66-72. 2012
  3. ncbi request reprint Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma
    Thai H Ho
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN Electronic address
    Urol Oncol 33:23.e9-23.e14. 2015
  4. pmc NRAS mutation status is an independent prognostic factor in metastatic melanoma
    John A Jakob
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:4014-23. 2012
  5. pmc Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma
    Jeanette E Eckel-Passow
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA
    Carcinogenesis 35:822-7. 2014
  6. ncbi request reprint Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2
    Richard W Joseph
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Immunother 35:711-5. 2012
  7. pmc Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma
    Richard W Joseph
    Division of Medical Oncology, Mayo Clinic Florida, Jacksonville, Florida
    Cancer 120:1059-67. 2014
  8. pmc Therapy for metastatic melanoma: the past, present, and future
    Laura Finn
    Division of Hematology and Oncology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Med 10:23. 2012
  9. pmc A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    Melanoma Res 22:294-301. 2012
  10. pmc ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma
    Jeanette E Eckel-Passow
    Department of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Urol 14:14. 2014

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Richard W Joseph
    Division of Medical Oncology, Mayo Clinic, Jacksonville, Florida
    Cancer Immunol Res 3:18-22. 2015
    ..The rashes in all three patients were relatively mild, allowing treatment to continue despite the rashes. Cancer Immunol Res; 3(1); 18-22. ©2014 AACR. ..
  2. pmc Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma
    Richard W Joseph
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Immunother 35:66-72. 2012
    ..56 vs. 1.97 y, P<0.0001), and trended toward a decreased response rate (7% vs. 21%, P=0.08). NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment...
  3. ncbi request reprint Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma
    Thai H Ho
    Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN Electronic address
    Urol Oncol 33:23.e9-23.e14. 2015
    ..We evaluated loss of PBRM1 and BAP1 staining in ccRCC, papillary RCC (pRCC), chromophobe RCC (chRCC), and RO tumors using an immunohistochemistry assay in which negative staining was associated with loss-of-function mutations...
  4. pmc NRAS mutation status is an independent prognostic factor in metastatic melanoma
    John A Jakob
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:4014-23. 2012
    ....
  5. pmc Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma
    Jeanette E Eckel-Passow
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA
    Carcinogenesis 35:822-7. 2014
    ..Upregulation of ENRAGE could lead to local, autocrine stimulation of the RAGE receptor and thus support cancer progression. ..
  6. ncbi request reprint Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2
    Richard W Joseph
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Immunother 35:711-5. 2012
    ..Prospective trials of HD IL-2 followed by ipilimumab could potentially identify patients most likely to benefit from a sequential approach of HD IL-2 followed by ipilimumab...
  7. pmc Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma
    Richard W Joseph
    Division of Medical Oncology, Mayo Clinic Florida, Jacksonville, Florida
    Cancer 120:1059-67. 2014
    ..In this study, we used a highly sensitive and specific immunohistochemistry (IHC) assay to test whether BAP1 expression is an independent marker of ccRCC-specific survival, particularly in patients with low-risk disease...
  8. pmc Therapy for metastatic melanoma: the past, present, and future
    Laura Finn
    Division of Hematology and Oncology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Med 10:23. 2012
    ..In this review we will discuss the advantages and limitations of the two new approved agents, current clinical trials designed to overcome these limitations, and future clinical trials that we feel hold the most promise...
  9. pmc A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    Melanoma Res 22:294-301. 2012
    ..05). Cilengitide was well tolerated by patients in both the treatment arms but had minimal clinical efficacy as a single-agent therapy for metastatic melanoma, and the efficacy was not related to baseline αvβ3 expression...
  10. pmc ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma
    Jeanette E Eckel-Passow
    Department of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    BMC Urol 14:14. 2014
    ..We used a multi-stage design to identify and validate genes that are associated with smoking-related ccRCC...
  11. ncbi request reprint Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma
    Sanjay P Bagaria
    Department of Surgery, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Cancer 119:1860-7. 2013
    ..The authors hypothesized that ultrathin melanomas that present with lymph node metastasis represent biologically aggressive lesions with a worse prognosis...
  12. ncbi request reprint c-MET expression in primary and liver metastases in uveal melanoma
    Faithlore P Gardner
    aDivision of Hematology Oncology bDepartment of Biomedical Informatics and Biostatics cDepartment of Pathology, Mayo Clinic Florida, Jacksonville, Florida dDepartment of Pathology eDepartment of Medical Oncology fDepartment of Ophthalmology, Mayo Clinic Rochester, Rochester, MN, USA
    Melanoma Res 24:617-20. 2014
    ..Metastatic lesions have higher expression of c-MET expression than primary tumors. Clinical trials involving c-MET inhibitors deserve further study in patients with uveal melanoma in both the adjuvant and metastatic setting. ..
  13. ncbi request reprint Age-period-cohort analysis of renal cell carcinoma in United States adults
    Mark D Tyson
    Department of Urology, Mayo Clinic, Phoenix, AZ, USA
    Urology 82:43-7. 2013
    ..To determine the extent to which the year of diagnosis, year of birth, and age at diagnosis influence the incidence trends of kidney cancer in the United States...
  14. pmc Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy
    Richard W Joseph
    Department of Melanoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4882-91. 2011
    ..However, little is known how clinical and pathologic features impact TIL outgrowth isolated from metastatic melanoma tumors...